Literature DB >> 11221883

Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation.

D M Loeb1, E Evron, C B Patel, P M Sharma, B Niranjan, L Buluwela, S A Weitzman, D Korz, S Sukumar.   

Abstract

We analyzed Wilms' tumor suppressor 1 (WT1) expression and its regulation by promoter methylation in a panel of normal breast epithelial samples and primary carcinomas. Contrary to previous reports, WT1 protein was strongly expressed in primary carcinomas (27 of 31 tumors) but not in normal breast epithelium (1 of 20 samples). Additionally, the WT1 promoter was methylated in 6 of 19 (32%) primary tumors, which nevertheless expressed WT1. The promoter is not methylated in normal epithelium. Thus, although tumor-specific methylation of WT1 is established in primary breast cancer at a low frequency, other transcriptional regulatory mechanisms appear to supercede its effects in these tumors. Our results demonstrate expression of WT1 in mammary neoplasia, and that WT1 may not have a tumor suppressor role in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11221883

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  77 in total

Review 1.  Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.

Authors:  Ann Van Driessche; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-01-30

2.  Opposite regulation of estrogen receptor-α and its variant ER-α36 by the Wilms' tumor suppressor WT1.

Authors:  Lianguo Kang; Lei Wang; Zhao-Yi Wang
Journal:  Oncol Lett       Date:  2011-01-21       Impact factor: 2.967

3.  The clinical significance of the alternative Wilms tumor gene overexpression-hypermethylation signature in acute myeloid leukemia.

Authors:  M El Bordiny; A Al-Ghandour; R A Abo Elwafa; O Fayed
Journal:  Clin Transl Oncol       Date:  2018-11-30       Impact factor: 3.405

4.  Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions.

Authors:  Adrian P Bracken; Nikolaj Dietrich; Diego Pasini; Klaus H Hansen; Kristian Helin
Journal:  Genes Dev       Date:  2006-04-17       Impact factor: 11.361

5.  Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.

Authors:  Nirali N Shah; David M Loeb; Hahn Khuu; David Stroncek; Tolu Ariyo; Mark Raffeld; Cindy Delbrook; Crystal L Mackall; Alan S Wayne; Terry J Fry
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-12       Impact factor: 5.742

6.  The Wilms' tumor suppressor WT1 induces estrogen-independent growth and anti-estrogen insensitivity in ER-positive breast cancer MCF7 cells.

Authors:  Lei Wang; Zhao-Yi Wang
Journal:  Oncol Rep       Date:  2010-04       Impact factor: 3.906

7.  Differential sensitization of two human colon cancer cell lines to the antitumor effects of irinotecan combined with 5-aza-2'-deoxycytidine.

Authors:  Shuko Hakata; Jun Terashima; Yu Shimoyama; Kouji Okada; Shiho Fujioka; Erika Ito; Wataru Habano; Shogo Ozawa
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

8.  Epigenetic silencing contributes to the loss of BRMS1 expression in breast cancer.

Authors:  Brandon J Metge; Andra R Frost; Judy A King; Donna Lynn Dyess; Danny R Welch; Rajeev S Samant; Lalita A Shevde
Journal:  Clin Exp Metastasis       Date:  2008-06-20       Impact factor: 5.150

Review 9.  Pleural mesothelial cells in pleural and lung diseases.

Authors:  Hitesh Batra; Veena B Antony
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

10.  Studies of Wilms' Tumor (WT1) Gene Expression in Adult Acute Leukemias in Singapore.

Authors:  Che Kang Lim; Yeow Tee Goh; William Y K Hwang; Liam Pock Ho; Li Sun
Journal:  Biomark Insights       Date:  2007-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.